PD-1/PD-L1 Immune Checkpoint Inhibitors in the Treatment of Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer: a Meta-analysis on Their Efficacy and Safety

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Oct 31

PMID 39478479

Authors

Zuxiu Wang

Peimeng You

Zhanglei Yang

Hanxi Xiao

Xinrong Tang

Yongping Pan

Xuhuan Li

Feng Gao

Affiliations

Soon will be listed here.

Abstract

Background: Triple negative breast cancer (TNBC) represents a particularly aggressive and clinically challenging subtype of breast cancer, characterized by its invasive nature and generally poor prognosis. Treatment options for unresectable TNBC are limited. In recent years, the advent of PD-1/PD-L1 immune checkpoint inhibitors has offered a promising new treatment option for unresectable TNBC. The role of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) in unresectable TNBC management remains a subject of debate. This article aims to synthesize evidence from randomized controlled trials (RCTs) through a meta-analysis (MA) to provide a comprehensive evaluation of the efficacy and safety profile of ICIs in the treatment of unresectable TNBC.

Method: We searched PubMed, Embase, Cochrane library, Web of Science, and ClinicalTrials.gov for the eligible RCTs which compared the efficacy and safety of PD-1/PD-L1 ICIs and chemotherapy alone. The outcomes analyzed included overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and treatment-related adverse effects (AEs).

Results: This meta-analysis included 11 trials. Therapy with PD-L1 inhibitors was superior to chemotherapy in terms of OS in both the intention-to-treat (ITT) population and the PD-L1-positive population. (ITT: HR: = 0.90 [0.81, 0.99], P = 0.04, I = 48%; PD-L1 + : HR = 0.82 [0.70, 0.95], P = 0.01, I = 64%); In terms of PFS, treatment with PD-L1 inhibitors prolonged PFS in both the ITT and PD-L1-positive populations compared with chemotherapy (ITT: HR: = 0.85 [0.77, 0.93], P = 0.0006, I = 46%; PD-L1 + : HR = 0.72 [0.62, 0.83], P < 0.00001, I = 70%, Fig. 5); Compared with chemotherapy alone, treatment with PD-1 inhibitors prolonged OS in both the PD-L1-positive and ITT populations. (ITT: HR = 0.87 [0.78, 0.96], P = 0.007, I = 71%; CPS ≥ 1: HR = 0.81 [0.71, 0.92], P = 0.001, I = 39%); In terms of PFS, therapy with PD-1 inhibitors improved PFS in both the ITT population and the PD-L1-positive population compared with chemotherapy. (ITT: HR = 0.79 [0.70, 0.90], P = 0.0004, I = 0%; CPS ≥ 1: HR = 0.71 [0.61, 0.83], P < 0.0001, I = 0%; CPS ≥ 10: HR = 0.67 [0.53, 0.84], P = 0.0008, I = 0%).

Conclusion: Both PD-1 and PD-L1 inhibitors can offer survival benefits to TNBC patients, with the primary beneficiaries being those who are PD-L1-positive. However, immunotherapy can also lead to an increase in treatment-related adverse events. Therefore, it is essential to conduct a risk assessment for each patient before starting treatment to prevent the occurrence of serious adverse reactions.

Trial Registration: This systematic review study has been filed with PROSPERO (Registration number: CRD42024571775).

References

Zhu Y, Zhu X, Tang C, Guan X, Zhang W . Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer. 2021; 1876(2):188593. DOI: 10.1016/j.bbcan.2021.188593. View

Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman D, Xiao N . Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014; 23(12):2965-70. DOI: 10.1158/1055-9965.EPI-14-0654. View

Iwata H, Inoue K, Kaneko K, Ito Y, Tsugawa K, Hasegawa A . Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Jpn J Clin Oncol. 2019; 49(12):1083-1091. PMC: 6935297. DOI: 10.1093/jjco/hyz135. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Hattori M, Masuda N, Takano T, Tsugawa K, Inoue K, Matsumoto K . Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355. Cancer Med. 2023; 12(9):10280-10293. PMC: 10225213. DOI: 10.1002/cam4.5757. View

Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J . Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024; 30(1):249-256. DOI: 10.1038/s41591-023-02677-x. View

Kwa M, Adams S . Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Cancer. 2018; 124(10):2086-2103. DOI: 10.1002/cncr.31272. View

Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N . Triple-negative breast cancer--current status and future directions. Ann Oncol. 2009; 20(12):1913-27. DOI: 10.1093/annonc/mdp492. View

Rigiracciolo D, Nohata N, Lappano R, Cirillo F, Talia M, Scordamaglia D . IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells. Cells. 2020; 9(4). PMC: 7225986. DOI: 10.3390/cells9041010. View

10.

Luen S, Virassamy B, Savas P, Salgado R, Loi S . The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016; 29:241-50. DOI: 10.1016/j.breast.2016.07.015. View

11.

Bachelot T, Filleron T, Bieche I, Arnedos M, Campone M, Dalenc F . Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat Med. 2021; 27(2):250-255. DOI: 10.1038/s41591-020-01189-2. View

12.

Winer E, Lipatov O, Im S, Goncalves A, Munoz-Couselo E, Lee K . Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(4):499-511. DOI: 10.1016/S1470-2045(20)30754-3. View

13.

Lin N, Vanderplas A, Hughes M, Theriault R, Edge S, Wong Y . Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012; 118(22):5463-72. PMC: 3611659. DOI: 10.1002/cncr.27581. View

14.

Miles D, Gligorov J, Andre F, Cameron D, Schneeweiss A, Barrios C . Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021; 32(8):994-1004. DOI: 10.1016/j.annonc.2021.05.801. View

15.

Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(9):569. DOI: 10.1038/nrc.2017.74. View

16.

Rossevold A, Andresen N, Bjerre C, Gilje B, Jakobsen E, Raj S . Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nat Med. 2022; 28(12):2573-2583. PMC: 9800277. DOI: 10.1038/s41591-022-02126-1. View

17.

Shah M, Osgood C, Amatya A, Fiero M, Pierce W, Nair A . FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res. 2022; 28(24):5249-5253. DOI: 10.1158/1078-0432.CCR-22-1110. View

18.

Dent R, Andre F, Goncalves A, Martin M, Schmid P, Schutz F . IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2024; 35(7):630-642. DOI: 10.1016/j.annonc.2024.04.001. View

19.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

20.

Fosu-Mensah N, Peris M, Weeks H, Cai J, Westwell A . Advances in small-molecule drug discovery for triple-negative breast cancer. Future Med Chem. 2015; 7(15):2019-39. DOI: 10.4155/fmc.15.129. View